ClinicalTrials.gg
TerminatedNCT03896945Updated Sep 29, 2026Results posted

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

A Phase 2/3 interventional study of Placebo and AVP-786 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 72 sites in 4 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Based on the Interim Analysis outcome and recommendation by the DMC, Otsuka approved termination of the study based on futility.
Updated Sep 29, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. — 3 open to participants now, 4 under way, 3 of them phase 3. Schizophrenia · Otsuka Holdings Co., Ltd..

Enrollment
55th of 111
136 · median 125
Started
2019
with 12 others
Phase 2/3
4 of 120
none open now
Registered
92nd of 120
by date

Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 55th largest by enrollment of the 111 interventional ones that give a count, is one of 13 that started in 2019, is one of 4 in phase 2/3, and was the 92nd registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786, as compared with placebo, for the treatment of negative symptoms of schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Negative Symptoms
  • Schizophrenia
  • AVP-786
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who meet the , 5th Edition (DSM-V) diagnostic criteria for schizophrenia confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I) Version 7.0.2
  • Participants must have well-controlled positive symptoms and prominent negative symptoms as defined by Positive and Negative Syndrome Scale (PANSS) criteria.
  • Participants currently receiving a second-generation atypical antipsychotic drug (SGA) are eligible if they are stable and adherent to their dosing schedule.
  • Participants must have a reliable informant (e.g., case manager, social worker, family member). The informant should be able to spend an adequate amount of time with the participant to be able to address behaviors, activities, and symptoms.

Exclusion criteria

Exclusion Criteria:

  • Participants with current major depressive disorder (MDD)
  • Participants with pseudo-parkinsonism secondary to their ongoing antipsychotic medication
  • Participants currently using anticholinergic medications
  • Participants recently hospitalized as in-patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Placebo comparator
    Placebo (Run-in Period)

    Participants received AVP-786 matching placebo capsules, orally, twice a day (BID) over a 3-week run-in period.

    Drug: Placebo

  • Experimental
    AVP-786

    Participants received AVP-786-28/4.9 (deudextromethorphan hydrobromide (d6-DM) 28 milligrams (mg)/quinidine sulfate (Q) 4.9 mg) capsule, along with AVP-786 matching placebo capsule, orally, once daily (QD) for 3 days followed by AVP-786-28/4.9 capsule, orally, BID for the next 4 days of titration period. Following the 1-week titration period, participants received AVP-786-42.63/4.9 (d6-DM 42.63 mg/Q 4.9 mg), orally, BID for the remaining 11 weeks of the DBT period.

    Drug: AVP-786

  • Placebo comparator
    Placebo

    Participants received AVP-786 matching placebo capsules, orally, BID over a 12-week DBT period.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline (Week 3) to Week 15 in the Positive and Negative Syndrome Scale (PANSS) Marder Negative Factors Score

    The PANSS is a validated clinical scale used as a reliable and valid measure of the negative and positive symptom of schizophrenia. PANSS consists of three subscales: a total of 30 disparate items. Each item's severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS marder negative factors score is comprised of the following 7 items of the 30-item PANSS: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity and flow of conversation, motor retardation and active social avoidance. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). PANSS total score range is 30 to 210, with higher scores indicating more severe symptoms. Negative change from baseline indicates improvement. Baseline is defined as the end of the placebo run-in period (Week 3), and to be the last assessment prior to the first dose of study drug.

    Time frame: Baseline (Week 3); Week 15

Secondary outcomes

  1. Change From Baseline (Week 3) to Week 15 in the Negative Symptom Assessment-16 (NSA-16) Global Negative Symptom Score

    NSA-16=clinician-rated scale assessing presence, severity, \& range of negative symptoms associated with schizophrenia. It consists of 16 items \& uses 5-factor model to describe negative symptoms: communication (1-4, range=4-24), emotional/affective (5-7, range=3-18), social involvement (8-10, range=3-18), motivational (11-14, range=4-24), \& retardation (15-16, range=3-18) \&Global Negative Symptom Rating. NSA-16 items are rated on 6-point scale, 1=behavior is normal to 6=behavior severely reduced. Each item admits score of 9 if item is not ratable. Global Negative Symptom Rating range is 1=no evidence of symptoms to 7=extremely severe symptoms. 16 items yield a total of 16-96, with higher score indicating greater clinical severity of symptoms. Global rating range is 1-7, with higher score indicating extremely severe symptom. If more than 3 items were not ratable, total score was not evaluable \& was regarded as missing. Negative change from baseline indicates improvement.

    Time frame: Baseline (Week 3); Week 15

  2. Change From Baseline (Week 3) to Week 15 in the Patient Global Impression of Severity (PGI-S) Score

    The severity of participants illness with respect to their schizophrenia was rated using a 7-point PGI-S. PGI-S scores range from 1 to 7, where 1= normal, not at all ill, 2= borderline ill, 3=mildly ill, 4=moderately ill, 5= markedly ill, 6=severely ill, 7=extremely ill. Missing PGI-S rating were not imputed. Negative change from baseline indicates improvement. Baseline is defined as the end of the placebo run-in period (Week 3), and to be the last assessment prior to the first dose of study drug.

    Time frame: Baseline (Week 3); Week 15

  3. Patient Global Impression of Change (PGI-C) Score

    The PGI-C is a 7-point (1-7) participant-rated scale used to assess treatment response with respect to schizophrenia as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, or 7 = very much worse. Missing PGI-C rating were not imputed. .

    Time frame: At Weeks 6, 9, 12 and 15

07

Results

Posted Sep 29, 2026

Participant flow

Participants took part in this study at 65 investigative sites in Bulgaria, Poland, and the United States including Puerto Rico from 15 February 2019 to 23 May 2023.

Phase A: Placebo Run-in Period
Participant flow — Phase A: Placebo Run-in Period
MilestonePlacebo (Run-in Period)AVP-786Placebo
Started13600
Placebo responders1000
Placebo non-responders11500
Completed12500
Not completed1100
Withdrew: Withdrawal by subject400
Withdrew: Reason not specified300
Withdrew: Lost to follow-up200
Withdrew: Non-compliance100
Withdrew: Protocol deviation100
Phase B: Double-blind Treatment Period
Participant flow — Phase B: Double-blind Treatment Period
MilestonePlacebo (Run-in Period)AVP-786Placebo
Started06560
Completed05752
Not completed088
Withdrew: Adverse event020
Withdrew: Lack of efficacy001
Withdrew: Noncompliance with study drug002
Withdrew: Physician decision010
Withdrew: Protocol deviation020
Withdrew: Study terminated by sponsor001
Withdrew: Withdrawal by subject034

Outcome measures

PrimaryChange From Baseline (Week 3) to Week 15 in the Positive and Negative Syndrome Scale (PANSS) Marder Negative Factors Score

The PANSS is a validated clinical scale used as a reliable and valid measure of the negative and positive symptom of schizophrenia. PANSS consists of three subscales: a total of 30 disparate items. Each item's severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS marder negative factors score is comprised of the following 7 items of the 30-item PANSS: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity and flow of conversation, motor retardation and active social avoidance. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). PANSS total score range is 30 to 210, with higher scores indicating more severe symptoms. Negative change from baseline indicates improvement. Baseline is defined as the end of the placebo run-in period (Week 3), and to be the last assessment prior to the first dose of study drug.

Time frame:
Baseline (Week 3); Week 15
Reported as:
Least squares mean · score on a scale
Change From Baseline (Week 3) to Week 15 in the Positive and Negative Syndrome Scale (PANSS) Marder Negative Factors Score
score on a scaleAVP-786Placebo
Change From Baseline (Week 3) to Week 15 in the Positive and Negative Syndrome Scale (PANSS) Marder Negative Factors Score-2.3 ± 0.47-2.5 ± 0.49
Statistical analysis
  • AVP-786 vs Placebo · MMRM · p = 0.768 (The mixed-effects model for repeated measures (MMRM) analysis included fixed effects for treatment, trial center, visit, treatment-by-visit interaction, and baseline-by-visit interaction. An unstructured covariance model was used.) · Least squares (ls) mean difference: 0.2 · 95% CI -1.09 to 1.47
SecondaryChange From Baseline (Week 3) to Week 15 in the Negative Symptom Assessment-16 (NSA-16) Global Negative Symptom Score

NSA-16=clinician-rated scale assessing presence, severity, \& range of negative symptoms associated with schizophrenia. It consists of 16 items \& uses 5-factor model to describe negative symptoms: communication (1-4, range=4-24), emotional/affective (5-7, range=3-18), social involvement (8-10, range=3-18), motivational (11-14, range=4-24), \& retardation (15-16, range=3-18) \&Global Negative Symptom Rating. NSA-16 items are rated on 6-point scale, 1=behavior is normal to 6=behavior severely reduced. Each item admits score of 9 if item is not ratable. Global Negative Symptom Rating range is 1=no evidence of symptoms to 7=extremely severe symptoms. 16 items yield a total of 16-96, with higher score indicating greater clinical severity of symptoms. Global rating range is 1-7, with higher score indicating extremely severe symptom. If more than 3 items were not ratable, total score was not evaluable \& was regarded as missing. Negative change from baseline indicates improvement.

Time frame:
Baseline (Week 3); Week 15
Reported as:
Least squares mean · score on a scale
Change From Baseline (Week 3) to Week 15 in the Negative Symptom Assessment-16 (NSA-16) Global Negative Symptom Score
score on a scaleAVP-786Placebo
Change From Baseline (Week 3) to Week 15 in the Negative Symptom Assessment-16 (NSA-16) Global Negative Symptom Score-0.4 ± 0.10-0.5 ± 0.10
Statistical analysis
  • AVP-786 vs Placebo · MMRM · p = 0.443 (The MMRM analysis included fixed effects for treatment, trial center, visit, treatment-by-visit interaction, and baseline-by-visit interaction. An unstructured covariance model was used.) · Ls mean difference: 0.1 · 95% CI -0.17 to 0.37
SecondaryChange From Baseline (Week 3) to Week 15 in the Patient Global Impression of Severity (PGI-S) Score

The severity of participants illness with respect to their schizophrenia was rated using a 7-point PGI-S. PGI-S scores range from 1 to 7, where 1= normal, not at all ill, 2= borderline ill, 3=mildly ill, 4=moderately ill, 5= markedly ill, 6=severely ill, 7=extremely ill. Missing PGI-S rating were not imputed. Negative change from baseline indicates improvement. Baseline is defined as the end of the placebo run-in period (Week 3), and to be the last assessment prior to the first dose of study drug.

Time frame:
Baseline (Week 3); Week 15
Reported as:
Least squares mean · score on a scale
Change From Baseline (Week 3) to Week 15 in the Patient Global Impression of Severity (PGI-S) Score
score on a scaleAVP-786Placebo
Change From Baseline (Week 3) to Week 15 in the Patient Global Impression of Severity (PGI-S) Score-0.3 ± 0.16-0.4 ± 0.16
Statistical analysis
  • AVP-786 vs Placebo · MMRM · p = 0.590 (The MMRM analysis included fixed effects for treatment, trial center, visit, treatment-by-visit interaction, and baseline-by-visit interaction. An unstructured covariance model was used.) · Ls mean difference: 0.1 · 95% CI -0.31 to 0.54
SecondaryPatient Global Impression of Change (PGI-C) Score

The PGI-C is a 7-point (1-7) participant-rated scale used to assess treatment response with respect to schizophrenia as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, or 7 = very much worse. Missing PGI-C rating were not imputed. .

Time frame:
At Weeks 6, 9, 12 and 15
Reported as:
Mean · score on a scale
Patient Global Impression of Change (PGI-C) Score
score on a scaleAVP-786Placebo
Week 63.1 ± 1.073.0 ± 1.05
Week 92.8 ± 1.102.9 ± 0.98
Week 122.9 ± 1.152.9 ± 1.05
Week 152.8 ± 1.202.9 ± 1.00
Statistical analysis
  • AVP-786 vs Placebo · Cochran-Mantel-Haenszel · p = 0.6377 (P-value and treatment difference (CI) were derived from Cochran-Mantel-Haenszel (CMH) row mean scores statistics controlling for study center.) · Treatment difference: 0.1 · 95% CI -0.31 to 0.51
  • AVP-786 vs Placebo · Cochran-Mantel-Haenszel · p = 0.4827 (P-value and treatment difference (CI) were derived from CMH row mean scores statistics controlling for study center.) · Treatment difference: -0.1 · 95% CI -0.51 to 0.24
  • AVP-786 vs Placebo · Cochran-Mantel-Haenszel · p = 0.8662 (P-value and treatment difference (CI) were derived from CMH row mean scores statistics controlling for study center.) · Treatment difference: 0.0 · 95% CI -0.43 to 0.36
  • AVP-786 vs Placebo · Cochran-Mantel-Haenszel · p = 0.6062 (P-value and treatment difference (CI) were derived from CMH row mean scores statistics controlling for study center.) · Treatment difference: -0.1 · 95% CI -0.51 to 0.30

Adverse events

Collected over From the first dose of the study drug to end of follow up period (Up to Week 19). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Run-in Period)0/136 (0%)0/136 (0%)20/136 (14.7%)
AVP-7860/65 (0%)2/65 (3.1%)25/65 (38.5%)
Placebo0/60 (0%)0/60 (0%)14/60 (23.3%)
Most frequent serious events
Most frequent serious events
EventPlacebo (Run-in Period)AVP-786Placebo
CellulitisInfections and infestations0/1361/650/60
PneumoniaInfections and infestations0/1361/650/60
Most frequent other events
Showing 10 of 64
Most frequent other events
EventPlacebo (Run-in Period)AVP-786Placebo
HeadacheNervous system disorders3/1362/652/60
Back painMusculoskeletal and connective tissue disorders0/1360/652/60
DizzinessNervous system disorders2/1362/651/60
ArthralgiaMusculoskeletal and connective tissue disorders0/1362/651/60
NasopharyngitisInfections and infestations1/1362/650/60
Gamma-glutamyltransferase increasedInvestigations0/1362/650/60
Weight increasedInvestigations0/1362/650/60
FallInjury, poisoning and procedural complications0/1362/650/60
HypertensionVascular disorders0/1362/650/60
SomnolenceNervous system disorders2/1360/651/60

Baseline characteristics

Randomized Sample included all participants randomized into the double-blind phase of this study.

Age, Continuous
Age, Continuous(years)AVP-786PlaceboTotal
Mean44.8 ± 9.5444.0 ± 10.2544.4 ± 9.86
Sex: Female, Male
Sex: Female, Male(Participants)AVP-786PlaceboTotal
Female202444
Male453681
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AVP-786PlaceboTotal
Hispanic or Latino6713
Not Hispanic or Latino424082
Unknown or Not Reported171330
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AVP-786PlaceboTotal
White141226
Black or African American333467
Asian101
Other011
Missing171330
Patient Global Impression of Change (PGI-C) Score
Patient Global Impression of Change (PGI-C) Score(score on a scale)AVP-786PlaceboTotal
Mean3.3 ± 0.913.5 ± 0.863.4 ± 0.89
08

Study locations

72 sites
  • Clinical Research Site
    Little Rock, Arkansas 72209, United States
  • Clinical Research Site #840-041
    Anaheim, California 92805, United States
  • Clinical Research Site #840-013
    Bellflower, California 90706, United States
  • Clinical Research Site #840-079
    Costa Mesa, California 92626, United States
  • Clinical Research Site #840-027
    Culver City, California 90230, United States
  • Clinical Research Site #840-006
    Garden Grove, California 92845, United States
  • Clinical Research Site #840-026
    Glendale, California 91206, United States
  • Clinical Research Site# 840-067
    La Habra, California 90631, United States
  • Clinical Research Site# 840-083
    Lafayette, California 94549, United States
  • Clinical Research Site 840-002
    Lemon Grove, California 91945, United States
  • Clinical Research Site
    Oakland, California 94607, United States
  • Clinical Research Site #840-035
    Oceanside, California 92056, United States
  • Clinical Research Site# 840-010
    Panorama City, California 91402, United States
  • Clinical Research Site #840-012
    Riverside, California 92506, United States
  • Clinical Research Site# 840-081
    San Bernardino, California 92408, United States
  • Clinical Research Site #840-005
    San Diego, California 92102, United States
  • Clinical Research Site #840-096
    Santee, California 92071, United States
  • Clinical Research Site #840-015
    Torrance, California 90502, United States
  • Clinical Research Site# 840-094
    Doral, Florida 33178, United States
  • Clinical Research Site #840-046
    Hollywood, Florida 33021, United States
  • Clinical Research Site Site #840-093
    Homestead, Florida 33030, United States
  • Clinical Research Site #840-062
    Lakeland, Florida 33803, United States
  • Clinical Research Site #840-024
    Largo, Florida 33770, United States
  • Clinical Research Site #840-032
    Miami, Florida 33122, United States
  • Clinical Research Site #840-080
    Miami, Florida 33173, United States
  • Clinical Research Site #840-084
    Miami Lakes, Florida 33014, United States
  • Clinical Research Site
    Okeechobee, Florida 34972, United States
  • Clinical Research Site # 840-102
    Weston, Florida 33331, United States
  • Clinical Research Site #840-088
    Atlanta, Georgia 30303, United States
  • Clinical Research Site #840-091
    Atlanta, Georgia 30318, United States
  • Clinical Research Site #840-008
    Atlanta, Georgia 30328, United States
  • Clinical Research Site #840-063
    Decatur, Georgia 30030, United States
  • Clinical Research Site
    Chicago, Illinois 60640, United States
  • Clinical Research Site #840-090
    Springfield, Illinois 62702, United States
  • Clinical Research Site
    Lake Charles, Louisiana 70629, United States
  • Clinical Research Site #840-098
    Shreveport, Louisiana 71101, United States
  • Clinical Research Site #840-072
    Worcester, Massachusetts 01605, United States
  • Clinical Research Site #840-057
    Flowood, Mississippi 39232, United States
  • Clinical Research Site #840-040
    Olivette, Missouri 63132, United States
  • Clinical Research Site #840-029
    Saint Charles, Missouri 63304, United States
  • Clinical Research Site #840-034
    Saint Charles, Missouri 63304, United States
  • Clinical Research Site
    St Louis, Missouri 63109, United States
  • Clinical Research Site #840-025
    St Louis, Missouri 63118, United States
  • Clinical Research Site #840-028
    Berlin, New Jersey 08009, United States
  • Clinical Research Site #840-009
    Jamaica, New York 11432, United States
  • Clinical Research Site #840-070
    New York, New York 10027, United States
  • Clinical Research Site
    Rochester, New York 14618, United States
  • Clinical Research Site #840-074
    Charlotte, North Carolina 28211, United States
  • Clinical Research Site #840-052
    Middleburg Heights, Ohio 44130, United States
  • Clinical Research Site
    Edmond, Oklahoma 73013, United States
  • Clinical Research Site #840-065
    Oklahoma City, Oklahoma 73112, United States
  • Clinical Research Site #840-061
    Media, Pennsylvania 19063, United States
  • Clinical Research Site
    Norristown, Pennsylvania 19401, United States
  • Clinical Research Site #840-099
    Myrtle Beach, South Carolina 28117, United States
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
  • Clinical Research Site
    DeSoto, Texas 75115, United States
  • Clinical Research Site #840-058
    Fort Worth, Texas 76104, United States
  • Clinical Research Site #840-018
    Richardson, Texas 75080, United States
  • Clinical Research Site
    San Antonio, Texas 78229, United States
  • Clinical Research Site #840-069
    Springville, Utah 84663, United States
  • Clinical Research Site #840-051
    Everett, Washington 98201, United States
  • Clinical Research Site #009
    Kazanlak, 6100, Bulgaria
  • Clinical Research Site #100-008
    Novi Iskar, 1282, Bulgaria
  • Clinical Research Site #100-007
    Plovdiv, 4004, Bulgaria
  • Clinical Research Site #100-004 2
    Sofia, 1680, Bulgaria
  • Clinical Research Site #100-006
    Veliko Tarnovo, 5000, Bulgaria
  • Clinical Research Site #100-001
    Vratsa, 3000, Bulgaria
  • Clinical Research Site
    Tuszyn, Woj.Iodzkie 95-080, Poland
  • Clinical Research Site #616-002
    Bełchatów, 97-400, Poland
  • Clinical Research Site #616-003
    Pruszcz Gdański, 80-300, Poland
  • Clinical Research Site #630-001
    San Juan, 918, Puerto Rico
  • Clinical Research Site # 630-002
    San Juan, 926, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in May 2023, 51 months.

Results were first posted in Sep 2026, 3 years 4 months after primary completion. A results delay was requested in May 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2019
First posted
Apr 1, 2019
StartActual
Feb 15, 2019
Primary completionActual
May 23, 2023
CompletionActual
May 23, 2023
Results delay requested
May 21, 2024
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 29, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 United States)
  • Clinical Research Site · St Louis, United States
  • Clinical Research Site #840-025 · St Louis, United States
Show 2 removed
  • Clinical Research Site · Saint Louis, United States
  • Clinical Research Site #840-025 · Saint Louis, United States
Sep 29, 2026
Interventions
Arms added: Placebo (Run-in Period)
Sep 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange fromFrom Baseline (Week 3) to Week 15 in the Positive and Negative Syndrome Scale (PANSS) Marder Negative Factors ScoreTime frame: Baseline; Week 15 → Baseline (Week 3); Week 15
Sep 29, 2026
Documents
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedChange fromFrom Baseline (Week 3) to Week 15 in the Negative Symptom Assessment-16 (NSA-16) Global Negative Symptom ScoreTime frame: Baseline; Week 15 → Baseline (Week 3); Week 15
  • EditedChange fromFrom Baseline (Week 3) to Week 15 in the Patient Global Impression of Severity (PGI-S) ScoreTime frame: Baseline; Week 15 → Baseline (Week 3); Week 15
  • EditedChange from Baseline to Week 15 in the Patient Global Impression of Change (PGI-C) ScoreTime frame: Baseline; Week 15 → At Weeks 6, 9, 12 and 15
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Results posted
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • Clinical Research Site · St Louis, United States
    • Clinical Research Site #840-025 · St Louis, United States
    Show 2 removed
    • Clinical Research Site · Saint Louis, United States
    • Clinical Research Site #840-025 · Saint Louis, United States
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange fromFrom Baseline (Week 3) to Week 15 in the Positive and Negative Syndrome Scale (PANSS) Marder Negative Factors ScoreTime frame: Baseline; Week 15 → Baseline (Week 3); Week 15
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedChange fromFrom Baseline (Week 3) to Week 15 in the Negative Symptom Assessment-16 (NSA-16) Global Negative Symptom ScoreTime frame: Baseline; Week 15 → Baseline (Week 3); Week 15
    • EditedChange fromFrom Baseline (Week 3) to Week 15 in the Patient Global Impression of Severity (PGI-S) ScoreTime frame: Baseline; Week 15 → Baseline (Week 3); Week 15
    • EditedChange from Baseline to Week 15 in the Patient Global Impression of Change (PGI-C) ScoreTime frame: Baseline; Week 15 → At Weeks 6, 9, 12 and 15
    Interventions Arms added: Placebo (Run-in Period)
    + 4 other changes: index terms, verification date, description and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03896945
Responsible party
Sponsor
First posted
Apr 1, 2019
Start date
Feb 15, 2019
Primary completion
May 23, 2023
Completion
May 23, 2023
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Deudextromethorphan · Quinidine

Start the discussion